These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22252622)

  • 1. Which tyrosine kinase inhibitor, if any?
    Ruiz-Arguelles GJ
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):878-9. PubMed ID: 22252622
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmaceuticals can be cost-effective in the long run].
    Jönsson B; Wilking N
    Lakartidningen; 2010 Apr 21-27; 107(16):1081-5. PubMed ID: 20476706
    [No Abstract]   [Full Text] [Related]  

  • 3. [Innovations with system disrupting potential? New drugs of high value].
    Pfannkuche MS; Glaeske G
    Pharm Unserer Zeit; 2008; 37(5):416-22. PubMed ID: 18729265
    [No Abstract]   [Full Text] [Related]  

  • 4. Bruton's tyrosine kinase as a drug discovery target.
    Pan Z
    Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
    Inokura K; Onishi Y; Shimosegawa K; Okitsu Y; Katsuoka Y; Fujiwara T; Fukuhara N; Ishizawa K; Harigae H
    Ann Hematol; 2012 Nov; 91(11):1825-6. PubMed ID: 22543830
    [No Abstract]   [Full Text] [Related]  

  • 6. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia: reversing the chronic phase.
    Goldman JM
    J Clin Oncol; 2010 Jan; 28(3):363-5. PubMed ID: 20008612
    [No Abstract]   [Full Text] [Related]  

  • 8. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tyrosine kinase inhibitor STI571--a breakthrough in leukemia treatment?].
    Czechowska A; Błasiak J
    Postepy Biochem; 2003; 49(3):157-67. PubMed ID: 15083608
    [No Abstract]   [Full Text] [Related]  

  • 10. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
    Deininger MW; Manley P
    Leuk Res; 2012 Mar; 36(3):253-61. PubMed ID: 21996558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.
    Jalkanen SE; Vakkila J; Kreutzman A; Nieminen JK; Porkka K; Mustjoki S
    Exp Hematol; 2011 Jan; 39(1):102-113.e1. PubMed ID: 20869423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule tyrosine kinase inhibitor and depression.
    Quek R; Morgan JA; George S; Butrynski JE; Polson K; Meyer F; Demetri GD; Block SD
    J Clin Oncol; 2009 Jan; 27(2):312-3. PubMed ID: 19064960
    [No Abstract]   [Full Text] [Related]  

  • 14. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
    Carmi C; Mor M; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
    Joensuu H
    Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Targeting Ras related proteins for leukemia therapy].
    Kimura S; Maekawa T
    Rinsho Ketsueki; 2005 Mar; 46(3):179-86. PubMed ID: 16447712
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of tyrosine kinase inhibitors in the management of high-grade gliomas.
    Ahluwalia MS; Patel M; Peereboom DM
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1739-48. PubMed ID: 22050023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 20. The era of targeted therapies: increasing role for novel oncologic drugs in dermatology.
    Montella L; Palmieri G; Lacouture M
    Arch Dermatol; 2007 Jun; 143(6):788-9. PubMed ID: 17576948
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.